[A13-28] Addendum to Commission A13-10 (pertuzumab)
Last updated 01.10.2013
Project no.:
A13-28
Commission:
Commission awarded on 06.08.2013 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment
| Project no. | Title | Status |
|---|---|---|
| A18-41 | Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A13-10 | Pertuzumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A22-103 | Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-102 | Pertuzumab/trastuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2013-10-01 A G-BA decision was published.